We are monitoring the impact of COVID-19 on Europe Influenza Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 1623
Share on
Share on

Europe Influenza Market Research Report – Segmented By Product Type, Consumer and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends and Forecasts (2019 - 2024)

Pulished: August, 2019
ID: 1623
Pages: 140

Europe Influenza Market Size (2019 - 2024)

The size of the Europe Influenza Market is expected to reach USD 1.99 billion by 2024 from USD 1.27 billion in 2019, growing at a CAGR of 9.52% during the forecast period, 2019 - 2024.

Influenza or flu is a transmittable respiratory disease that affects the nose, throat, and lungs. Influenza viruses are basically of three types-Type A (H1N1, H2N2, and H5N1, etc.), Type B, and Type C. It can be either seasonal, pandemic, or zoonotic. Influenza can be fatal if goes unnoticed and is regarded as a major reason for mortality, globally. Some of the symptoms of influenza are fever, cough, sore throat, runny or stuffy nose, fatigue, headache, and body ache. Children below 2 years of age and elderly above 65 years of age are at high risk of developing chronic flu. As per a recent report, a large number of older people in Europe were severely infected by the influenza virus in 2014-2015, resulting in a huge loss of human lives.

The growth of the market is majorly driven by factors such as a boost in Research & Development investment, rising public awareness, the boost in healthcare expenditure, and the introduction of new medicines.

The key restraints of the market are the antigenic shift of influenza virus and side-effects of the product (soreness, allergic reactions, swelling, and redness).

Europe Influenza Market is segmented on the basis of Product Type and Consumer. Based on Product Type, the market is classified into vaccines and drugs. On the basis of Consumer, the market is classified into Children and Adults.

The European market is geographically segmented into the United Kingdom, Spain, Germany, Italy, and France and the rest of Europe.

The major companies dominating the market are Sanofi-Pasteur (U.S.), AstraZeneca (United Kingdom), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), GlaxoSmithKline (U.K.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan), CSL Limited (Australia).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)     

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product Type                             

                                5.1.1 Introduction           

                                5.1.2 Vaccines   

                                5.1.3 Drugs         

                                5.1.4  Y-o-Y Growth Analysis, By Product              

                                5.1.5  Market Attractiveness Analysis, By Product            

                                5.1.6  Market Share Analysis, By Product              

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Safety Biomarkers

                                5.2.3 Efficacy Biomarkers             

                                5.2.4 Validation Biomarkers        

                                5.2.5  Y-o-Y Growth Analysis, By Type    

                                5.2.6  Market Attractiveness Analysis, By Type  

                                5.2.7  Market Share Analysis, By Type    

                5.3 Application                 

                                5.3.1 Introduction           

                                5.3.2 Diagnostics Development 

                                5.3.3 Drug Discovery and Development

                                5.3.4 Personalised Medicine      

                                5.3.5 Disease Risk Assessment  

                                5.3.6 Other Applications               

                                5.3.7  Y-o-Y Growth Analysis, By Application        

                                5.3.8  Market Attractiveness Analysis, By Application      

                                5.3.9  Market Share Analysis, By Application       

                5.4 Disease Indications                 

                                5.4.1 Introduction           

                                5.4.2 Cancer      

                                5.4.3 CardiovascularDisorders    

                                5.4.4 Neurological Disorders       

                                5.4.5 Immunological Disorders  

                                5.4.6 Other Diseases      

                                5.4.7  Y-o-Y Growth Analysis, By Disease Indications        

                                5.4.8  Market Attractiveness Analysis, By Disease Indications      

                                5.4.9  Market Share Analysis, By Disease Indications       

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By Type

                                                6.1.3.4 By Application

                                                6.1.3.5 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By Type

                                                6.1.4.4 By Application

                                                6.1.4.5 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By Type

                                                6.1.5.4 By Application

                                                6.1.5.5 By Indication

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Sanofi-Pasteur                          

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 AstraZeneca                               

                8.3 F. Hoffmann-La Roche                           

                8.4 Novartis                       

                8.5 GlaxoSmithKline                       

                8.6 Pfizer Inc.                    

                8.7 Merck & Co.                               

                8.8 Abbott Laboratories                               

                8.9 Mitsubishi Tanabe Pharma Corporation                         

                8.10 CSL Limited                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Influenza Market By Product Type, From 2019 - 2024 ( USD Billion )
  2. Europe Vaccines Market By Region, From 2019 - 2024 ( USD Billion )
  3. Europe Drugs Market By Region, From 2019 - 2024 ( USD Billion )
  4. Europe Influenza Market By Consumer, From 2019 - 2024 ( USD Billion )
  5. Europe Children Market By Region, From 2019 - 2024 ( USD Billion )
  6. Europe Adults Market By Region, From 2019 - 2024 ( USD Billion )
  7. U.K. Influenza Market By Product Type, From 2019 - 2024 ( USD Billion )
  8. U.K. Influenza Market By Consumer, From 2019 - 2024 ( USD Billion )
  9. Germany Influenza Market By Product Type, From 2019 - 2024 ( USD Billion )
  10. Germany Influenza Market By Consumer, From 2019 - 2024 ( USD Billion )
  11. France Influenza Market By Product Type, From 2019 - 2024 ( USD Billion )
  12. France Influenza Market By Consumer, From 2019 - 2024 ( USD Billion )
  13. Italy Influenza Market By Product Type, From 2019 - 2024 ( USD Billion )
  14. Italy Influenza Market By Consumer, From 2019 - 2024 ( USD Billion )
  15. Spain Influenza Market By Product Type, From 2019 - 2024 ( USD Billion )
  16. Spain Influenza Market By Consumer, From 2019 - 2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample